| Year |
Citation |
Score |
| 2023 |
Perusini MA, Novitzky-Basso I, Atenafu EG, Forrest D, Bence-Bruckler I, Savoie L, Keating MM, Busque L, Delage R, Xenocostas A, Liew E, Laneuville P, Paulson K, Stockley T, Lipton JH, et al. Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study. British Journal of Haematology. PMID 37697469 DOI: 10.1111/bjh.19058 |
0.344 |
|
| 2020 |
Banerji V, Anglin P, Christofides A, Doucette S, Laneuville P. Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia. Current Oncology (Toronto, Ont.). 27: e231-e245. PMID 32489274 DOI: 10.3747/Co.27.6291 |
0.391 |
|
| 2019 |
Daher-Reyes GS, Bence-Bruckler I, Busque L, Forrest DL, Savoie L, Keating M, Delage R, Xenocostas A, Liew E, Laneuville P, Paulson K, Lipton JH, Kamel-Reid S, Leber B, Kim DDH. BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission Blood. 134: 2933-2933. DOI: 10.1182/Blood-2019-131454 |
0.319 |
|
| 2019 |
Kim DDH, Bence-Bruckler I, Busque L, Forrest DL, Savoie L, Keating M, Delage R, Xenocostas A, Liew E, Laneuville P, Paulson K, Lipton JH, Kamel-Reid S, Leber B. The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up Blood. 134: 1644-1644. DOI: 10.1182/Blood-2019-128283 |
0.336 |
|
| 2019 |
Berinstein N, Bence-Buckler I, Laneuville P, Stewart D, Smyth L, Kerr C, Klein G, Pennell N, Roos-Assar K. SPIReL: PHASE 2 STUDY DPX-SURVIVAC WITH INTERMITTENT LOW DOSE CYCLOPHOSPHAMIDE AND PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA Hematological Oncology. 37: 569-569. DOI: 10.1002/Hon.16_2632 |
0.34 |
|
| 2018 |
Klil-Drori AJ, Yin H, Azoulay L, Del Corpo A, Harnois M, Gratton MO, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE. Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia. Cancer. PMID 30423211 DOI: 10.1002/Cncr.31835 |
0.358 |
|
| 2018 |
Grand'Maison F, Yeung M, Morrow SA, Lee L, Emond F, Ward BJ, Laneuville P, Schecter R. Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches. Neural Regeneration Research. 13: 1871-1874. PMID 30233054 DOI: 10.4103/1673-5374.239432 |
0.321 |
|
| 2018 |
Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica. PMID 30093398 DOI: 10.3324/Haematol.2018.188987 |
0.423 |
|
| 2018 |
Grand'Maison F, Yeung M, Morrow SA, Lee L, Emond F, Ward BJ, Laneuville P, Schecter R. Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment. Current Medical Research and Opinion. 1-38. PMID 29583054 DOI: 10.1080/03007995.2018.1458023 |
0.317 |
|
| 2018 |
Laneuville P. When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Current Treatment Options in Oncology. 19: 15. PMID 29520446 DOI: 10.1007/S11864-018-0532-2 |
0.422 |
|
| 2018 |
Kim DDH, Busque L, Forrest DL, Savoie L, Bence-Bruckler I, Couban S, Delage R, Xenocostas A, Liew E, Laneuville P, Paulson K, Lipton JH, Kamel-Reid S, Leber B. Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial Blood. 132: 787-787. DOI: 10.1182/Blood-2018-99-114656 |
0.368 |
|
| 2017 |
Klil-Drori AJ, Yin H, Azoulay L, Harnois M, Gratton MO, Del Corpo A, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE. Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response. American Journal of Hematology. PMID 28670773 DOI: 10.1002/Ajh.24838 |
0.356 |
|
| 2017 |
Laneuville P. Stopping second-generation TKIs in CML. Blood. 129: 805-806. PMID 28209750 DOI: 10.1182/Blood-2016-12-757302 |
0.425 |
|
| 2017 |
Laneuville P, Larouche JF, Tosikyan A, Christofides A. ASCO 2017 meeting summary: updates to practice-changing studies in untreated non-Hodgkin lymphoma Current Oncology. 24: 262-270. DOI: 10.3747/Co.24.3797 |
0.314 |
|
| 2017 |
Kim D, Bence-Bruckler I, Forrest DL, Savoie L, Couban S, Busque L, Delage R, Laneuville P, Liew E, Xenocostas A, Paulson K, Kamel-Reid S, Lipton JH, Leber B. Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD) Blood. 130: 1622-1622. DOI: 10.1182/Blood.V130.Suppl_1.1622.1622 |
0.397 |
|
| 2016 |
Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J, Fergusson D, Halpenny M, Hamelin L, Huebsch L, Hutton B, ... Laneuville P, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet (London, England). PMID 27291994 DOI: 10.1016/S0140-6736(16)30169-6 |
0.341 |
|
| 2016 |
Flowers CR, Costa LJ, Pasquini MC, Le-Rademacher J, Lill M, Shore TB, Vaughan W, Craig M, Freytes CO, Shea TC, Horwitz ME, Fay JW, Mineishi S, Rondelli D, Mason J, ... ... Laneuville P, et al. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase 2 Study and CIBMTR Outcomes. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 27040394 DOI: 10.1016/J.Bbmt.2016.03.018 |
0.379 |
|
| 2016 |
Klil-Drori AJ, Azoulay L, Yin H, Corpo AD, Harnois M, Gratton M, Chamakhi I, Delage R, Mollica L, Laneuville P, Olney HJ, Busque L, Assouline SE. Timely Molecular Monitoring and Achievement of Major Molecular Response in Chronic Myeloid Leukemia Blood. 128: 3072-3072. DOI: 10.1182/Blood.V128.22.3072.3072 |
0.307 |
|
| 2016 |
Kanakry JA, Hong F, Martinez-Maza O, Horning SJ, Gordon LI, Gascoyne RD, Gellert LL, Lemas MV, Cheson B, Advani RH, Pohlman B, Kenkre VP, Winter JN, Stiff PJ, Tuscano J, ... ... Laneuville P, et al. Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial Blood. 128: 2992-2992. DOI: 10.1182/Blood.V128.22.2992.2992 |
0.324 |
|
| 2016 |
Kim DDH, Bence-Bruckler I, Forrest DL, Savoie ML, Couban S, Busque L, Delage R, Laneuville P, Liew E, Xenocostas A, Paulson K, Kamel-Reid S, Lipton JH, Leber B. Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial Blood. 128: 1922-1922. DOI: 10.1182/Blood.V128.22.1922.1922 |
0.427 |
|
| 2015 |
Sirhan S, Busque L, Foltz L, Grewal K, Hamm C, Laferriere N, Laneuville P, Leber B, Liew E, Olney HJ, Prchal J, Porwit A, Gupta V. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. Clinical Lymphoma, Myeloma & Leukemia. PMID 26433906 DOI: 10.1016/J.Clml.2015.07.650 |
0.398 |
|
| 2015 |
Peltier L, Brown R, Monczak Y, Popradi G, Storring J, Laneuville P. Development of a New Third-Party Unit for Adult Stem Cell Transplantation using Clinical-Grade Rejected Cord Blood Units Journal of Genetic Syndromes & Gene Therapy. 6: 1-11. DOI: 10.4172/2157-7412.1000254 |
0.353 |
|
| 2015 |
Klil-Drori AJ, Azoulay L, Yin H, Gratton M, Harnois M, Chamakhi I, Delage R, Laneuville P, Mollica L, Olney HJ, Busque L, Assouline SE. Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia Blood. 126: 2778-2778. DOI: 10.1182/Blood.V126.23.2778.2778 |
0.391 |
|
| 2013 |
Lill M, Costa LJ, Yeh RF, Lim S, Stuart R, Waller EK, Shore T, Craig M, Freytes CO, Shea TC, Rodriguez TE, Flinn IW, Comeau T, Yeager AM, Pulsipher MA, ... ... Laneuville P, et al. Pharmacokinetic-Directed Dose Adjustment Is Essential for Intravenous Busulfan Exposure Optimization: Findings From a Multi-Center Phase II Study of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma in North America Biology of Blood and Marrow Transplantation. 19: S132. DOI: 10.1016/J.Bbmt.2012.11.067 |
0.32 |
|
| 2012 |
Van der Jagt R, Laneuville P, Macdonald D, Stewart D, Christofides A, Sehn LH. A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Current Oncology (Toronto, Ont.). 19: 160-8. PMID 22670095 DOI: 10.3747/Co.19.1064 |
0.421 |
|
| 2012 |
Costa LJ, Lill M, Yeh RF, Stuart RK, Lim S, Waller EK, Shore TB, Craig M, Freytes CO, Shea TC, Rodriguez TE, Flinn IW, Comeau T, Pulsipher MA, Bence-Bruckler I, ... Laneuville P, et al. Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America Blood. 120: 813-813. DOI: 10.1182/Blood.V120.21.813.813 |
0.375 |
|
| 2012 |
Laneuville P. High Risk of Error in Categorizing Treatment Response in Individual CML Patients by Standard Cytogenetic Analysis or PCR Assay with High CV: A Bayesian Analysis Blood. 120: 3776-3776. DOI: 10.1182/Blood.V120.21.3776.3776 |
0.37 |
|
| 2011 |
Laneuville P, Baccarani M, Cortes JE, Hochhaus A, Kantarjian H, Shah NP, Bradley-Garelik MB, Zhu C, Porkka K. Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6605. PMID 28020270 DOI: 10.1200/Jco.2011.29.15_Suppl.6605 |
0.347 |
|
| 2011 |
Delage R, Turner AR, Leber B, Hasegawa WS, Roy D, Savoie ML, Leitch HA, Bence-Bruckler I, Forrest DL, Kanjeekal S, Sandeep S, Laneuville P, Assouline S, Grewal K, Kovacs MJ, et al. A Canadian Expanded Access Trial of Oral Nilotinb in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Blood. 118: 4437-4437. DOI: 10.1182/Blood.V118.21.4437.4437 |
0.429 |
|
| 2010 |
Laneuville P, DiLea C, Yin OQP, Woodman RC, Mestan J, Manley PW. Comparative in vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia Journal of Clinical Oncology. 28: e169-e171. PMID 20194843 DOI: 10.1200/Jco.2009.26.4945 |
0.337 |
|
| 2010 |
How J, Warner M, Shustik C, Laneuville P. Cytarabine and Etoposide (CYVE) as First-Line Therapy for Primary Central Nervous System Lymphoma Blood. 116: 4895-4895. DOI: 10.1182/Blood.V116.21.4895.4895 |
0.392 |
|
| 2010 |
Younes A, Bociek RG, Kuruvilla J, Laneuville P, Fung HC, Drouin M, Patterson T, Besterman J, Martell RE. Mocetinostat (MGCD0103), An Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, Produces Clinical Responses In Relapsed/Refractory Hodgkin Lymphoma (HL): Update From a Phase II Clinical Study Blood. 116: 1763-1763. DOI: 10.1182/Blood.V116.21.1763.1763 |
0.409 |
|
| 2009 |
Laneuville P, DiLea C, Mestan J, Yin O, Woodman RC, Manley P. Comparative in Vitro Cellular Data Alone Is Insufficient to Predict Clinical Responses and Guide Choice of BCR-ABL Inhibitor to Treat Imatinib-Resistant Chronic Myeloid Leukemia. Blood. 114: 510-510. DOI: 10.1182/Blood.V114.22.510.510 |
0.303 |
|
| 2007 |
Costa V, McGregor M, Laneuville P, Brophy JM. The cost-effectiveness of stem cell transplantations from unrelated donors in adult patients with acute leukemia. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 10: 247-55. PMID 17645679 DOI: 10.1111/J.1524-4733.2007.00180.X |
0.323 |
|
| 2006 |
Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. The New England Journal of Medicine. 354: 2623-4. PMID 16775249 DOI: 10.1056/Nejmc053425 |
0.378 |
|
| 2006 |
Assouline S, Sylvestre MP, Carriere P, Shustik C, Laneuville P. Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients. Transfusion. 46: 174-9. PMID 16441591 DOI: 10.1111/J.1537-2995.2006.00695.X |
0.375 |
|
| 2006 |
Laneuville P, Barnett MJ, Belanger R, Couban S, Forrest DL, Roy D, Lipton JH. Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia Current Oncology. 13: 201-221. DOI: 10.3747/Co.V13I6.124 |
0.399 |
|
| 2004 |
Cournoyer D, Toffelmire EB, Wells GA, Barber DL, Barrett BJ, Delage R, Forrest DL, Gagnon RF, Harvey EA, Laneuville P, Patterson BJ, Poon MC, Posen GA, Messner HA. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. Journal of the American Society of Nephrology : Jasn. 15: 2728-34. PMID 15466278 DOI: 10.1097/01.Asn.0000140219.28618.9F |
0.304 |
|
| 2003 |
Atkins H, Freedman M, Bowman M, Antel J, Arnold D, Bence-Bruckler I, Bar-Or A, Chen J, Cheynier R, Corsini R, Duquette P, Halpenny M, Huebsch L, Laneuville P, Lapierre Y, et al. 148Immunoablative therapy with purified autologous stem cells rescue for the treatment of poor prognosis MS Biology of Blood and Marrow Transplantation. 9: 110. DOI: 10.1016/S1083-8791(03)80149-0 |
0.307 |
|
| 1992 |
Laneuville P, Sun G, Timm M, Vekemans M. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl. Blood. 80: 1788-1797. DOI: 10.1182/Blood.V80.7.1788.1788 |
0.311 |
|
| Show low-probability matches. |